Aurora (TSX:ACB) Stock Just Slumped 26% Yesterday!

Aurora Cannabis (TSX:ACB) stock lost a quarter of its market value after the company disclosed intentions to raise US$125 million in equity capital.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Shares of pot giant Aurora Cannabis (TSX:ACB)(NYSE:ACB) fell over 26% on November 10 after it gained 176% in the previous six trading days. Aurora stock also fell 16.4% in after-hours trading on the NYSE yesterday.

Aurora Cannabis and peers gained momentum, as Joe Biden won the U.S. presidential race. During the pre-election debate, Vice-President-Elect Kamala Harris had emphasized the need to decriminalize marijuana at the federal level in the U.S., which sent pot stocks soaring after the Democrats won the election.

On November 9, Aurora Cannabis also disclosed its fiscal first quarter of 2021 results and reported net revenue of $67.8 million, indicating a 1% sequential gain and a fall of 10% year over year.

The company reported an adjusted EBITDA loss of $57.9 million, which includes restructuring costs of $47.4 million. After accounting for these charges, EBITDA loss stood at $10.5 million. Aurora claimed it is in compliance with its September 30th term debt covenants and is on the road to achieving a positive EBITDA in the December quarter.

Aurora Cannabis sales declined in Q1

Aurora stock gained 15% after its Q1 results, as it had forecast sales between $60 million and $64 million. While ACB beat its own guidance, its sales were up just marginally up on a sequential basis.

Aurora divested a few of its non-core businesses in the last few quarters, which contributed to its less-than-impressive revenue growth. However, its net cannabis sales fell 4% year over year in Q1, which means it is losing market share in a highly competitive but fast-growing space.

Aurora said its consumer cannabis net revenue totaled $34.3 million, which was 3% lower than sales in the prior-year period. This figure could have been lower, as Aurora confirmed consumer cannabis revenue was driven higher by $1.1 million due to its U.S. CBD sales after it acquired Reliva earlier this year.

Comparatively, Canopy Growth also reported its quarterly results, growing sales by 23% year over year to a record high of $135.3 million.

What’s next for ACB stock investors?

While Aurora expects to achieve a positive EBITDA in Q2, its operating loss stood at $107.2 million in the September quarter. The company is trying to grow the bottom line by slashing costs instead of top-line growth, which will make long-term investors nervous.

ACB also said it aims to achieve a positive free cash flow by the end of fiscal 2021, which will also mean it will not have to issue equity shares and dilute shareholder wealth. However, ACB stock lost a quarter of its market value yesterday after it announced another public offering.

Aurora said it will issue company units at a price of US$7.5 to raise US$125 million. Each unit will comprise one common share and one half of one common share purchase warrant. Further, each warrant will be exercisable to acquire one common share of ACB at an exercise price of US$9. Aurora stock closed trading at US$8.3 on November 10.

It’s clear that Aurora Cannabis will have to improve profit margins and cash flow in the near term, or the stock will experience another free fall from current prices and continue to burn investor wealth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Forget Canopy Growth: 1 Cannabis Stock With Far Less Risk

Cannabis stocks like Canopy Growth (TSX:WEED) haven't done well for quite some time, yet this one deserves a major boost!

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Canopy Growth Stock Worth Buying?

Canopy Growth stock (TSX:WEED) made a big move to consolidate its shares, but will this help the company move forward?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Corp: Will it Ever Be a Buy?

Canopy Growth Corp (TSX:WEED) keeps going lower. Will it ever find a bottom?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks a Good Buy in November 2023?

Cannabis stocks have slumped a long way down in the last few years, so is November the time to get…

Read more »

A cannabis plant grows.
Cannabis Stocks

2 Top Cannabis Stocks to Buy on the TSX Today

Two cannabis stocks are the top picks as the market moves toward consolidation and stability.

Read more »